

Christopher Jones

ASSOCIATE

Washington, D.C. | 202.626.8358

chris.jones@polsinelli.com



Chris Jones is an experienced patent litigator that focuses his practice on Hatch-Waxman and life sciences patent litigation. Chris has developed a deep understanding of the Hatch-Waxman litigation process and has litigated cases involving Abbreviated New Drug Applications (ANDAs), 505(b)(2) applications (sometimes referred to as “paper NDAs”), and more. He has experience at all stages of Hatch-Waxman cases and has litigated cases through trial both in United States District Courts and at the Patent Trial and Appeal Board (PTAB). Chris also has experience advising clients on the Food and Drug Administration (FDA) approval process, and understands the importance of balancing the complexities of FDA regulatory and patent litigation issues.

Chris has a diverse background in chemical and biochemical technologies, including pharmaceutical chemistry, organic chemistry, solid-state chemistry, biochemistry, polymer chemistry and cell biology. As a graduate student, his research focused on drug development and formulation, specifically the development and characterization of solid and crystalline forms of new and existing drug compounds. Prior to graduate school, Chris performed research projects related to the synthesis and characterization of polymers, organic compounds useful in the field of agricultural chemistry and also worked in a cell biology laboratory on the development of cancer therapies.

While earning his J.D. at George Mason University School of Law, Chris worked as a patent agent and technology specialist, where he used his background in chemistry to assist patent attorneys with opinion preparation and patent prosecution matters. He was a member of the Intellectual Property Law Society and graduated with a concentration in intellectual property law.

Education

- Antonin Scalia Law School - George Mason University (J.D., 2018)
 - Patent Law Track
 - Intellectual Property Law Society
- University of South Florida (M.A., 2014)
 - Chemistry
 - USF Fellow

Capabilities

- Hatch-Waxman & Biologics
- Intellectual Property
- Patent Litigation
- Life Sciences

- High Point University (B.S., *Dean's List*, 2012)
 - Chemistry
 - Presidential Scholar

Bar Admissions

- District of Columbia
- Admitted to practice before the United States Patent and Trademark Office

Matters

Chris has represented and advised clients in Hatch-Waxman cases involving blockbuster drug products, including: Revlimid (lenalidomide), Pomalyst (pomalidomide), Symbicort (budesonide/formoterol), Victoza (liraglutide), Ozempic and Wegovy (semaglutide), Entresto (sacubitril/valsartan), Bendeka and Belrapzo (bendamustine), Abilify Maintena (aripiprazole), Venclexta (venetoclax), and Sprycel (dasatinib).

Publications

May 18, 2026

Federal Circuit Addresses Prosecution History Estoppel, Disclosure-Dedication Rule in Affirming ANDA Product Noninfringement Decision

November 7, 2025

Federal Circuit Denies Challenges to USPTO Director's Discretionary Denial Decisions

September 16, 2025

Deference Ruling Could Close The FAR Loophole

Co-Author, Law360

April 24, 2025

Drug Pricing and Payment Executive Order Shows Trump Administration's Cards

March 14, 2025

Judge Connolly (D. Del.) Overturns \$96 Million Molecular Diagnostics Jury Verdict, Finds Patents Invalid Under § 112

March 11, 2025

Federal Circuit Affirms District Court's Obviousness Judgment on ImmunoGen Patent Application

February 6, 2025

New PTAB Guidance on Enabling Requirement Under § 102 of the AIA and Construction of Chemical Compound

